Clinical Study Of Efficacy Of Yigankang, Lamivudine Combined With Immunoregulator On Low ALT Level Chronic Hepatitis B

Hepatitis B virus (HBV) infection remains a life-threatening worldwide public health problem. And the antiviral therapy displays a key role for treatment of chronic hepatitis B. There is a relationship between pretreatment alanine aminotransaminases (ALT) level and antiviral efficacy. Patients with original lower serum ALT levels have often a weak and restricted immune response and low response rate. Immunomodulators can enhance immune responsiveness and augment specific lymphocyte function. Combinations of antiviral drug and immunomodulator may result in greater sustained response rates. Furthermore, hepatic fibrosis may occur in early stage of CHB and cause liver cirrhosis in severe patients. So it has clinical significance with antifibrotic drug at early stage of CHB.Objects: To assess the clinical antifibrotic and antiviral efficacy of Yigankang, LMV and immunomodulators in CHB patients with ALT≤80IU/L.Methods: Ninety-two patients were recruited in the study. Admitted criteria for our study were: age between 18 and 65 years, detectable hepatitis B s antigen (HBsAg) in serum, serum...